Almirall SA

Almirall SA

Almirall SA

Date Founded



Ronda General Mitre, 151,Barcelona, Catalonia 08022

Type of Company


Employees (Worldwide)



Wholesale: Consumer Non-Durables/Sundries

Company Description

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Executives & Employees

Chief Executive Officer

Executive Vice President Finance & Chief Financial Officer

Corporate Director & General Counsel

Executive Vice President R&D & Chief Scientific Officer

Executive Vice President, Global Commercial Operations

Vice President, Legal

Vice President, Manufacturing & Technical Services

Director-Internal Audit

Executive Vice President, Global Commercial Strategy

Board of Directors

Former Chairman & Chief Executive Officer at Almirall SA

Former Partner at Prodes SA

Executive Vice President, Corporate Marketing at The Estée Lauder Companies, Inc.

Professional at Academy of Medical Sciences

Chief Executive Officer at Almirall SA

Former Partner at Booz Allen Hamilton, Inc.

Professor at Instituto de Estudios Superiores de la Empresa

Venture Partner at Ysios Capital Partners SGEIC SA

Former Head, Division of Medical Representatives at Almirall SA

Corporate Director & General Counsel at Almirall SA

Paths to Almirall SA
Potential Connections via
Relationship Science
Almirall SA
Owners & Shareholders
Details Hidden

Generali Investments France is an active manager which follows a risk-cautious, fundamentals-based approach in order to generate consistent, low volatility returns over the long-term and protect invested capital.The firm combines top-down and bottom-up inputs provided by in-house research teams. They first analyze macro-economic indicators and the general political environment to evaluate their potential impact on the main financial markets. Dedicated committees decide on the strategic asset allocation and provide short-term forecast on equity and fixed-income markets driving tactical allocation to be implemented by the portfolio managers who select securities based on inputs from proprietary bottom-up securities analysis, ESG screening and quantitative models.Their bottom-up research team covers mainly European, US and Asian companies, providing equity recommendations and internal credit ratings to portfolio managers, who combine the positive aspects of equity analysis (expectations on revenues and profitability evolution) and credit analysis (debt distribution and cash flows) to analyze companies in an organic manner and identify the financial instrument with the most attractive risk/return profile (equities, convertible bonds, corporate bonds).Risk management is fully integrated in the firm's investment process and provides daily inputs to portfolio managers along with ex-ante analysis (VaR, simulations, expected yield) and ex-post risk profile measurements (tracking error and tracking error volatility, turnovers, risk and return ratios). A risk platform runs various analyses including stress testing, VaR measurement, risk sources analysis, delta adjusted market exposures and sensitivities.

Details Hidden

Adelphi actively invests in European equity across sectors and market-caps. Their Adelphi Europe portfolio is invested in mid- and large-cap Western European equity. Their Adelphi Emerging Europe strategy is invested across all market capitalisations and industries in Eastern Europe. Both funds follow an equity long/short investment style to maximize absolute returns and minimize volatility. The firm also manages a long-only version of their Adelphi Europe portfolio.Fund managers make the investment decisions, and focus on fundamental research to identify attractive securities.

Details Hidden

AzValor Asset Management SGIIC SA, a subsidiary of Inversiones Mobiliarias Advalor SL, is a Spanish company located in Madrid that provides investment advice. The firm was founded in 2008 by Carlos Fernández-Rubíes de Lillo and Santiago Moro Olivera. Beltrán Parages Revertera is the current CEO, occupying that position since 2015.

Recent Transactions
Details Hidden

Almirall SA purchases Allergan USA Inc /Acne & Dermatoses Five Brands from Allergan Plc

Details Hidden

Grupo Corporativo Landon SL purchases Almirall SA

Details Hidden

Grünenthal GmbH purchases Almirall De Mexico, S.A. De C.V. from Almirall SA

Transaction Advisors
Investment Advisor

Advised onAlmirall SA purchases ThermiAesthetics LLC

Legal Advisor

Advised onAlmirall SA purchases Aqua Pharmaceuticals LLC from Roundtable Healthcare Management, Inc.

Legal Advisor

Advised onAlmirall SA purchases Poli Group Holding SRL


Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Legal Advisor

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA


Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Advisors & Consultants
Legal Advisor

Partner at White & Case LLP


Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The U.S. Diversified Products segment refers to the sales in the U.S. of pharmaceutical products, over-the-counter products, and medical device products in the areas of neurology and certain other therapeutics classes, including aesthetics and generic products in the U.S. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Key Stats and Financials As of 2017
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value Sales
Enterprise Value EBITDAOperating
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It currently markets ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company was founded in April 2009 and is headquartered in Santa Barbara, CA.

GW Pharmaceuticals Plc Pharmaceuticals | Cambridge, CA

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Sun Pharmaceutical Industries Ltd. Wholesale: Consumer Non-Durables/Sundries | Mumbai, MA

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Vectura Group Plc Pharmaceuticals | Chippenham, WI

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. It operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. The company was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Almirall SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Almirall SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Almirall SA.